$AWH
Aspira Women's Health Inc.

2021 Q1 Form 10-K Financial Statement

#000092661721000033 Filed on March 31, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $1.496M $4.651M $1.310M
YoY Change 22.62% 2.49% 42.39%
Cost Of Revenue $893.0K $3.415M $790.0K
YoY Change 11.63% 2.15% 5.33%
Gross Profit $603.0K $1.236M $520.0K
YoY Change 43.57% 3.43% 205.88%
Gross Profit Margin 40.31% 26.57% 39.69%
Selling, General & Admin $5.617M $17.11M $3.680M
YoY Change 46.85% 10.73% 28.22%
% of Gross Profit 931.51% 1384.55% 707.69%
Research & Development $872.0K $2.104M $240.0K
YoY Change 120.76% 106.68% 84.62%
% of Gross Profit 144.61% 170.23% 46.15%
Depreciation & Amortization $90.00K $265.0K $50.00K
YoY Change 60.71% -20.42% -66.67%
% of Gross Profit 14.93% 21.44% 9.62%
Operating Expenses $6.489M $19.22M $3.920M
YoY Change 53.77% 16.66% 30.67%
Operating Profit -$5.886M -$17.98M -$3.400M
YoY Change 54.89% 17.69% 20.14%
Interest Expense -$20.00K $10.00K $20.00K
YoY Change -300.0% -83.33%
% of Operating Profit
Other Income/Expense, Net -$10.00K $66.00K $0.00
YoY Change -111.63% -466.67%
Pretax Income -$5.920M $17.91M -$3.390M
YoY Change 59.57% 17.52% 20.21%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings -$5.920M -$17.91M -$3.390M
YoY Change 59.74% 17.51% 20.21%
Net Earnings / Revenue -395.72% -384.97% -258.78%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$54.48K -$0.18 -$34.83K
COMMON SHARES
Basic Shares Outstanding 111.7M 100.7M 97.24M
Diluted Shares Outstanding 100.7M

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.40M $16.60M $11.70M
YoY Change 633.33% 41.88% 24.47%
Cash & Equivalents $59.37M $16.60M $11.70M
Short-Term Investments
Other Short-Term Assets $1.000M $1.100M $800.0K
YoY Change 25.0% 37.5% 33.33%
Inventory $71.00K $0.00 $25.00K
Prepaid Expenses
Receivables $952.0K $900.0K $924.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $61.37M $18.60M $13.41M
YoY Change 514.59% 38.81% 24.3%
LONG-TERM ASSETS
Property, Plant & Equipment $533.0K $1.000M $353.0K
YoY Change 67.61% 150.0% -41.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $13.00K
YoY Change -100.0% -100.0% 8.33%
Total Long-Term Assets $924.0K $1.000M $418.0K
YoY Change 151.77% 150.0% -32.58%
TOTAL ASSETS
Total Short-Term Assets $61.37M $18.60M $13.41M
Total Long-Term Assets $924.0K $1.000M $418.0K
Total Assets $62.30M $19.60M $13.83M
YoY Change 501.73% 42.03% 21.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.587M $1.100M $855.0K
YoY Change -0.5% -8.33% -10.0%
Accrued Expenses $3.471M $3.600M $2.588M
YoY Change 60.4% 38.46% 41.81%
Deferred Revenue
YoY Change
Short-Term Debt $400.0K $600.0K $303.0K
YoY Change 106.19% 200.0% 60.32%
Long-Term Debt Due $201.0K $1.000M $193.0K
YoY Change
Total Short-Term Liabilities $6.100M $6.400M $3.978M
YoY Change 53.07% 60.0% 34.21%
LONG-TERM LIABILITIES
Long-Term Debt $2.718M $3.100M $1.099M
YoY Change 158.86% 181.82% -14.94%
Other Long-Term Liabilities $400.0K $400.0K $13.00K
YoY Change 2400.0%
Total Long-Term Liabilities $2.718M $3.500M $1.112M
YoY Change 154.97% 218.18% -13.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.100M $6.400M $3.978M
Total Long-Term Liabilities $2.718M $3.500M $1.112M
Total Liabilities $10.00M $9.900M $5.090M
YoY Change 97.98% 94.12% 19.6%
SHAREHOLDERS EQUITY
Retained Earnings -$446.0M -$422.2M
YoY Change 4.72% 3.74%
Common Stock $112.0K $97.00K
YoY Change 15.46% 29.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.33M $9.700M $8.738M
YoY Change
Total Liabilities & Shareholders Equity $62.30M $19.60M $13.83M
YoY Change 501.73% 42.03% 21.21%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$5.920M -$17.91M -$3.390M
YoY Change 59.74% 17.51% 20.21%
Depreciation, Depletion And Amortization $90.00K $265.0K $50.00K
YoY Change 60.71% -20.42% -66.67%
Cash From Operating Activities -$5.255M -$14.73M -$2.880M
YoY Change 50.1% 13.64% 25.22%
INVESTING ACTIVITIES
Capital Expenditures $41.00K $490.0K -$10.00K
YoY Change 78.26% 268.42% -80.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$41.00K -$490.0K -$10.00K
YoY Change 78.26% 268.42% -80.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $48.24M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.03M 20.15M -50.00K
YoY Change -102300.0% 30.51% 0.0%
NET CHANGE
Cash From Operating Activities -5.255M -14.73M -2.880M
Cash From Investing Activities -41.00K -490.0K -10.00K
Cash From Financing Activities 48.03M 20.15M -50.00K
Net Change In Cash 42.74M 4.928M -2.940M
YoY Change -1296.81% 110.33% 22.5%
FREE CASH FLOW
Cash From Operating Activities -$5.255M -$14.73M -$2.880M
Capital Expenditures $41.00K $490.0K -$10.00K
Free Cash Flow -$5.296M -$15.22M -$2.870M
YoY Change 50.28% 16.23% 27.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.19
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2019Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
350000
CY2020Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
616000
CY2019Q4 us-gaap Inventory Net
InventoryNet
25000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
37000
CY2020Q4 us-gaap Inventory Net
InventoryNet
30000
CY2019Q4 awh Deferred Tax Assets Intangible Assets Amortization
DeferredTaxAssetsIntangibleAssetsAmortization
2810000
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 dei Entity Public Float
EntityPublicFloat
290267539
CY2020 dei Entity Registrant Name
EntityRegistrantName
Aspira Women's Health Inc.
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2019 awh Effective Income Tax Rate Reconciliation Net Operating Loss Carry Forwards
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwards
0.23
CY2020 awh Effective Income Tax Rate Reconciliation Net Operating Loss Carry Forwards
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwards
-0.02
CY2019 awh Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.01
CY2020 awh Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.01
CY2020 awh Net Changes In Accounts Payable Related To Capital Expenditures
NetChangesInAccountsPayableRelatedToCapitalExpenditures
8000
CY2019 awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
52000
CY2020 awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
354000
CY2020Q4 awh Net Overstatement Of Deferred Tax Assets
NetOverstatementOfDeferredTaxAssets
2641350
CY2020Q4 awh Deferred Tax Assets Intangible Assets Amortization
DeferredTaxAssetsIntangibleAssetsAmortization
2495000
CY2019 awh Proceeds From Issuance Of Common Stock In Conjunction With Exercise Of Underwriters Option To Purchase Additional Shares In Connection With Public Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockInConjunctionWithExerciseOfUnderwritersOptionToPurchaseAdditionalSharesInConnectionWithPublicOfferingNetOfIssuanceCosts
2092000
CY2020 awh Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
1005000
CY2020 awh Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5060000
CY2019 awh Unrecognized Tax Benefits Return To Provision True Up
UnrecognizedTaxBenefitsReturnToProvisionTrueUp
-210000
CY2020 awh Unrecognized Tax Benefits Return To Provision True Up
UnrecognizedTaxBenefitsReturnToProvisionTrueUp
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei City Area Code
CityAreaCode
512
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
CY2020 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0000926617
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
111716852
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity File Number
EntityFileNumber
001-34810
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Trading Symbol
TradingSymbol
AWH
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
855000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1149000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
924000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
865000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1229000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1874000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2588000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3618000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
679000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
803000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2381000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2577000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
430802000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
449680000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9423216
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8212112
CY2019Q4 us-gaap Assets
Assets
13828000
CY2020Q4 us-gaap Assets
Assets
19605000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
13410000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18603000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9360000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11703000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16631000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2343000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4928000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97286157
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104619876
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97286157
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104619876
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
97000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
105000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Concentration of Credit Risk</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of </font><font style="display: inline;">$250,000</font><font style="display: inline;">, but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">&#xFEFF;</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31873000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
40000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28939000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32740000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
124000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
CY2020Q4 us-gaap Contractual Obligation
ContractualObligation
3088000
CY2020Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
253000
CY2020Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
599000
CY2020Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
588000
CY2020Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
508000
CY2020Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
564000
CY2020Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
576000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3343000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3415000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
31873000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35235000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35195000
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
40000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
40000
CY2019 us-gaap Depreciation
Depreciation
333000
CY2020 us-gaap Depreciation
Depreciation
265000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
333000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
265000
CY2019 us-gaap Dilutive Securities
DilutiveSecurities
CY2020 us-gaap Dilutive Securities
DilutiveSecurities
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.42
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2019 us-gaap Finite Lived Intangible Assets Cost Incurred To Renew Or Extend
FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend
203000
CY2020 us-gaap Finite Lived Intangible Assets Cost Incurred To Renew Or Extend
FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend
322000
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-55000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5810000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8270000
CY2019 us-gaap Gross Profit
GrossProfit
1195000
CY2020 us-gaap Gross Profit
GrossProfit
1236000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
15236000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
17905000
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
971000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1594000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
138000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-59000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-67000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
209000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
319000
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
59000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
38000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
567000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
64000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
63000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
123000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
116000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
106000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
95000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
135000
CY2019Q4 us-gaap Liabilities
Liabilities
5090000
CY2020Q4 us-gaap Liabilities
Liabilities
9886000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13828000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19605000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3978000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6400000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
1292000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
4076000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
193000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
999000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1099000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3077000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15441000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20152000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-133000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-490000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12965000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14734000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-15237000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17905000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15237000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17905000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15237000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17905000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
39000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
409000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
52000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
406000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
26000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0938
CY2019 us-gaap Operating Expenses
OperatingExpenses
16473000
CY2020 us-gaap Operating Expenses
OperatingExpenses
19217000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-15278000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-17981000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
432000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
330000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
325000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
66000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
133000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
490000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
758000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1077000
CY2020 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Reclassification</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">Certain prior year amounts have been reclassified to conform to the current year presentation with no material effect on the consolidated financial statements.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">&#xFEFF;</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13521000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10641000
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2000000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1637000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5060000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-422161000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440066000
CY2019 us-gaap Revenues
Revenues
4538000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
583000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2734000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3160000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
353000
CY2019 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
189000
CY2020 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
191000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1018000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2104000
CY2019 us-gaap Royalty Expense
RoyaltyExpense
176000
CY2020 us-gaap Royalty Expense
RoyaltyExpense
181000
CY2020 us-gaap Revenues
Revenues
4651000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y10M24D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.79
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0230
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0071
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9645000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8843000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1193000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1548000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
202576
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
356940
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
8000000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5178819
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
10955683
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6504934
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3439000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
691025
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1220500
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
691025
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.79
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1388900
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2711585
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3925409
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.55
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.87
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
303995
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4612005
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6612878
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.67
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.67
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M1D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2869000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3254000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.32
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.02
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
1.56
CY2020 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.47
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3743698
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
8212112
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
1.49
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y6M4D
CY2020 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.80
CY2019Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
303000
CY2020Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
611000
CY2020 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1366000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
7152000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8738000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9719000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
19687
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13521000
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
10641000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
250000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
182000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1637000
CY2020 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
192000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10967000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10644000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10517000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
21000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
65000
CY2019 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
134000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (&#x201C;GAAP&#x201D;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company&#x2019;s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company&#x2019;s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">&#xFEFF;</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86595581
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100723303
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86595581
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100723303
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86595581
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100723303

Files In Submission

Name View Source Status
0000926617-21-000033-index-headers.html Edgar Link pending
0000926617-21-000033-index.html Edgar Link pending
0000926617-21-000033.txt Edgar Link pending
0000926617-21-000033-xbrl.zip Edgar Link pending
awh-20201231.xml Edgar Link completed
awh-20201231.xsd Edgar Link pending
awh-20201231x10k.htm Edgar Link pending
awh-20201231xex21_0.htm Edgar Link pending
awh-20201231xex23_1.htm Edgar Link pending
awh-20201231xex31_1.htm Edgar Link pending
awh-20201231xex31_2.htm Edgar Link pending
awh-20201231xex32_0.htm Edgar Link pending
awh-20201231xex4_7.htm Edgar Link pending
awh-20201231_cal.xml Edgar Link unprocessable
awh-20201231_def.xml Edgar Link unprocessable
awh-20201231_lab.xml Edgar Link unprocessable
awh-20201231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending